Free Trial

GSK (GSK) News Today

GBX 1,734
-6.00 (-0.34%)
(As of 03:43 AM ET)
GSK to sell entire Haleon stake
GSK (LON:GSK) Is Paying Out A Dividend Of £0.15
GSK (LON:GSK) Reaches New 12-Month High at $1,767.50
GSK (LON:GSK) Sets New 12-Month High at $1,767.50
GSK's (GSK) Equal Weight Rating Reiterated at Barclays
Barclays reiterated an "equal weight" rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research report on Tuesday.
GSK (LON:GSK) Price Target Increased to GBX 1,660 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. boosted their price objective on shares of GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the stock an "underweight" rating in a research note on Thursday.
GSK (LON:GSK) Sets New 1-Year High After Dividend Announcement
GSK (LON:GSK) Sets New 12-Month High After Dividend Announcement
GSK plc (LON:GSK) to Issue GBX 15 Dividend
GSK plc (LON:GSK) declared a dividend on Wednesday, May 1st. Investors of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share on Thursday, July 11th. This represents a yield of 0.9%. The ex-dividend date of this dividend is Thursday, May 16th. The official announcement can be seen at this link.
GSK (LON:GSK) Earns Buy Rating from Shore Capital
Shore Capital reiterated a "buy" rating on shares of GSK in a report on Wednesday.
Deutsche Bank Aktiengesellschaft Reaffirms "Buy" Rating for GSK (LON:GSK)
Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,950 ($24.27) target price on shares of GSK in a research note on Wednesday.
GSK May 2024 28.000 call (GSK240517C00028000)
GSK plc (LON:GSK) Given Average Rating of "Hold" by Analysts
Shares of GSK plc (LON:GSK - Get Free Report) have earned a consensus rating of "Hold" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given
GSK (LON:GSK) Earns "Equal Weight" Rating from Barclays
Barclays reissued an "equal weight" rating and issued a GBX 1,725 ($21.65) target price on shares of GSK in a research note on Monday.
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment (GSK)
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

A once-in-a-century investment opportunity (Ad)

It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead.

To get its name and ticker symbol for free - just click here.

GSK Media Mentions By Week

GSK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GSK
News Sentiment

0.04

0.82

Average
Medical
News Sentiment

GSK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GSK Articles
This Week

7

7

GSK Articles
Average Week

Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (LON:GSK) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners